Investing.com — Shares in Pfizer (NYSE:) slumped in early trading on Friday after the drugmaker said that the twice-daily form of its new oral obesity treatment will not advance into late-stage studies.
In a statement, Pfizer said that the drug candidate, danuglipron, demonstrated “statistically significant” weight loss of as much as 13% at 32 weeks in the study’s participants.
But data from the phase two trial of the drug showed that mild gastrointestinal side effects were seen at a “high rate” in patients using the medication, Pfizer added. Discontinuation rates were subsequently “greater than 50%,” it noted.
As a result, the company said that any future development of danuglipron would be focused on its once-daily oral pill. Data on this formulation is expected to be unveiled in the first half of next year.
Pharmaceutical firms have been racing to secure a cheap, oral obesity drug, particularly after the soaring popularity of a weight-loss injection from Danish group Novo Nordisk (NYSE:). According to Morgan Stanley, growing demand for these treatments could push the value of the global obesity drug market up from $2.4 billion in 2022 to $77 billion in 2030.